- cafead Apr 18, 2019 at 10:22: AM
via Gilead-partnered immunotherapy developer Hookipa has been working on technology using arenaviruses — a family of viruses typically hosted by rodents — to turbocharge the human immune system to fight infectious diseases and cancers. The Vienna-based company on Wednesday priced a downsized IPO at the low end of its range at $14, raising gross proceeds of $84 million.
article source
article source